title: [Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of the combination of sorafenib and transarterial chemoembolization (TACE)in the treatment of primary hepatocellular carcinoma (HCC).
  
  
  METHODS
  The clinical data of 10 patients with unresectable HCC treated by sorafenib combined with TACE in the Department of Radiology, the First Hospital of China Medical University were retrospectively analyzed. The efficacy was evaluated according to the modified Response Evaluation Criteria in Solid Tumors assessment. Survival was analyzed by Kaplan-Meier method. Safety was evaluated according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0.
  
  
  RESULTS
  Among the 10 patients, 2 achieved complete response, 3 achieved partial response, 3 achieved stable disease, and 2 experienced progressive disease. The median overall survival of the cohort was 29.5 months. Different degree of adverse drug reactions (ADRs) occurred in 9 patients but all were at grade 3 or lower. The most common ADRs were hand-foot skin reaction (7/10) and diarrhea (6/10).
  
  
  CONCLUSIONS
  The combination of sorafenib and TACE is an effective and safe treatment for HCC.
authors.affiliation: Translational Medicine Research Center on Liver Cancer of Liaoning Province, Key Laboratory of Medical Imaging and Interventional Therapy, Department of Radiology, the First Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Lu-feng
authors.initials: LF
authors.lastname: Chen
authors.affiliation: Translational Medicine Research Center on Liver Cancer of Liaoning Province, Key Laboratory of Medical Imaging and Interventional Therapy, Department of Radiology, the First Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Hong-ying
authors.initials: HY
authors.lastname: Su
authors.affiliation: Translational Medicine Research Center on Liver Cancer of Liaoning Province, Key Laboratory of Medical Imaging and Interventional Therapy, Department of Radiology, the First Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Ke
authors.initials: K
authors.lastname: Xu
authors.affiliation: Translational Medicine Research Center on Liver Cancer of Liaoning Province, Key Laboratory of Medical Imaging and Interventional Therapy, Department of Radiology, the First Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Hai-bo
authors.initials: HB
authors.lastname: Shao
authors.affiliation: Translational Medicine Research Center on Liver Cancer of Liaoning Province, Key Laboratory of Medical Imaging and Interventional Therapy, Department of Radiology, the First Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Song-nian
authors.initials: SN
authors.lastname: Liang
authors.affiliation: Translational Medicine Research Center on Liver Cancer of Liaoning Province, Key Laboratory of Medical Imaging and Interventional Therapy, Department of Radiology, the First Hospital of China Medical University, Shenyang 110001, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib